Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Recruiting now · Phase 1
Conditions studied: Geographic Atrophy (GA)
In brief
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to see how safe and tolerable the study drug is when used as an injection in the eye. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Key facts
- Study ID
- NCT07230834
- Run by
- Regeneron Pharmaceuticals
- People needed
- 54
- Starts
- 2026-01-19
- Expected to finish
- 2028-07-03
- Last updated by the study team
- 2026-08-05
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Colorado Retina Associates — Lakewood, Colorado, United States (enrolling)
- Ophthalmic Consultants of Boston — East Weymouth, Massachusetts, United States (enrolling)
- Austin Retina Associates — Austin, Texas, United States (enrolling)
- Retina Foundation of the Southwest — Dallas, Texas, United States (enrolling)
- Retina Consultants Texas — The Woodlands, Texas, United States (enrolling)
- Arensia Exploratory Medicine at the Research Institute of Clinical Medicine — Tbilisi, Georgia (enrolling)
- Emanuelli Research and Development Center — Arecibo, Puerto Rico (enrolling)
- ARENSIA Clinics SRL — Bucharest, Romania (enrolling)
- Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca — Cluj-Napoca, Romania (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.